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Objectil·es. The aim of this study was to compare the myocar-
dial retention of technetium·99m (Tc·99m) sestamibi and thaI· 
lium·2Ot over a wide range of blood flow at different time points 
after tracer injection. 
Background. Technetium·99m sestamibi has been proposed as 
a new perfusion tracer with better physical characteristics than 
those of thallium·20t for scintigraphic imaging. Howeyer, no 
studies have simultaneously compared the ability of both tracers 
to assess myocardial. blood flow during pharmacologic l'asodila· 
tion. 
Methods. The myocardial retention of Tc·99m sestamibi and 
thallium·20t were compared over a wide range of blood flow 
induced by regional coronary occlusion and dipyridamole infusion 
in an open chest dog model. Myocardial retention of both tracers 
was determined by in ,'itro tissue counting at 2, 5 and 20 min after 
tracer injection and was correlated with microsphere·determined 
blood flow. 
Noninvasive evaluation of myocardial perfusion is most 
frequently performed by scintigraphic approaches with use 
of planar and tomographic imaging techniques. Although 
thallium-201 is the most widely applied single-photon agent 
for myocardial perfusion imaging, it is considered subopti· 
mal because of its low emission energy level (69 to 80 keY) 
and its long physical half-life of 72 h. To circumvent the phys-
ical limitations of thallium-201, technetium·99m (Tc-99m) 
derivatives have been proposed as alternative perfusion 
tracers (1,2). The higher emission energy of Tc-99m 
(140 keY) is better suited for camera characteristics and the 
shorter half-life of this agent allows larger injectable doses, 
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Results. Thallium·20t demonstrated greater absolute tissue 
retention than did Tc·99m sestamibi. At 2 min after tracer 
injection, there was an almost linear relation between the reten· 
tion of both tracers and myocardial blood flow O\'er a wide flow 
range. Howe\"er, this relation was not maintained over time. At 
20 min after injection, the retention of both tracers underesti· 
mated myocardial blood flow at higher flow rates. At 2, 5 and 
20 min after injection, increments of relatiye tracer retention 
between the different levels of flow were always greater for 
thallium·20t than for Tc·99m sestamibi. 
Conclusions. Thallium·20t displays more suitable physiologic 
characteristics as a flow tracer and may allow better differentia· 
tion of myocardial regions with different levels of coronary flow 
reser\"e. For both tracers, early cardiac imaging may minimize 
underestimation of blood flow at higher flow rates. 
(J Am Coil CardioI1992;20:1277-83) 
thus improving image quality. In addition, Tc-99m deriva-
tives are also appealing tracers because they allow simulta-
neous evaluation of myocardial blood flow and regional wall 
motion, which may increase the diagnostic specificity for 
detection of coronary artery disease. 
However, the fundamental kinetic requirement for a 
perfusion tracer is ability to accumulate in the myocardial 
tissue in proportion to the rate of coronary blood flow. This 
ability determines its accuracy as a myocardial perfusion 
tracer in nuclear cardiac imaging. This point has become 
particularly critical because the clinical use of coronary 
vasodilators (dipyridamole and adenosine, for example) re-
sults in a fourfold to fivefold increase of blood flow in normal 
vessel-related territories (3-6). 
At present, two Tc-99m derivatives (technetium-99m 
sestamibi and technetium-99m teboroxime) are commer-
cially available for clinical use. Tc-99m sestamibi, a lipo-
philic cationic Tc-99m complex, has been most widely 
evaluated in clinical trials (7-16). Although it achieves better 
image quality than that of thallium-201 (11-14), it has not 
been shown to provide higher diagnostic accuracy. It has 
been previously demonstrated in animal studies that Tc-99m 
sestamibi accumulates in the myocardium proportionally to 
regional blood flow (17-19) and that its myocardial clearance 
is slower than that of thallium·201 (20-24). However, its 
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Figure I. Experimental protocol. Ic = technetium. 
extraction fraction decreases~s flow increases (20,21). De-
spite numerous studies defining the myocardial extraction 
and retention characteristics of thallium-201 and Tc-99m 
sestamibi, to our knowledge, no investigations have simul-
taneously compared the accuracy of both tracers in assess-
ing myocardial blood flow during pharmacologic coronary 
vasodilation. Therefore, the purpose of the present study 
was to evaluate the myocardial retention characteristics of 
thallium-201 and Tc-99m sestamibi in comparison with those 
of microspheres over a wide range of blood flow at different 
intervals after injection. 
Methods 
This study protocol (Fig. I) was approved by the Com-
mittee for Animal Research at the University of Michigan 
and performed in accordance with the "Position of the 
American Heart Association on Research Animal Use" 
adopted November II, 1984 by the American Heart Associ-
ation. 
Experimental Preparation 
Nine mongrel dogs (mean weight 19.3 ± 3.0 kg) were 
anesthetized with sodium pentobarbital (30 mg/kg body 
weight). The dogs were intubated and ventilated with room 
air. A peripheral venous catheter was inserted for the 
administration of fluids as necessary and for subsequent 
dipyridamole infusion. Both femoral arteries were cathet'er-
ized for continuous aortic pressure monitoring and arterial 
blood sampling. The electrocardiogram (ECG) was also 
continuously recorded. The heart was then exposed by 
means of a left thoracotomy and suspended in a pericardial 
cradle. A left atrial catheter was inserted through the left 
atrial appendage for microsphere and isotope injection. The 
position of the catheter in the left atrium was confirmed by a 
left atrial pressure tracing. The proximal segment of the left 
anterior descending coronary artery was dissected free of 
the pericardium and a snare placed loosely around it for 
subsequent occlusion. 
Experimental Protocol 
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After stabilization of blood pressure and heart rate, 
0.56 mg/kg of dipyridamole was infused intravenously for 
4 min. At the end of this infusion, the left anterior descend-
ing coronary artery was occluded by the snare. After stabi-
lization of the hemodynamic variables, micro spheres labeled 
with niobium (Nb)-95 (10 /LCi, DuPont, NEN products), 
500 /LCi of Tc-99m sestamibi and 250 /Lei of thallium-201 
were simultaneously injected into the left atrium. The arte-
rial input function for microspheres was determined by 
arterial blood collection with a Harvard pump for 2 min. 
Arterial input function for both tracers was determined by 
serial arterial blood sampling for 2 min (group I = 2 dogs), 
5 min (group II = 3 dogs) and 20 min (group III = 4 dogs). At 
the end of the blood sampling, the dogs were killed by 
injection of a saturated solution of potassium chloride. The 
heart was then quickly excised. Atrial, right ventricular and 
connective tissue was trimmed away. The It!ft ventricle was 
cut along the short axis into slices I mm thick. Each left 
ventricular slice was then sectioned into samples of approx-
imately I g. Each myocardial sample was weighed. The 
activity in myocardial and blood samples was counted with 
use of a multichannel well counter (Packard model 5780). 
Energy windows were defined for Tc-99m (116 to 160 keY), 
thallium-201 (30 to 200 keY) and Nb-95 (710 to 820 keY). 
Blood and tissue samples were counted for Tc-99m immedi-
ately after the study. After allowing decay for Tc-99m (at 
least 12 half-lives of Tc-99m), the samples were counted for 
thallium-201 activity. The spillover of thallium-201 activity 
into the Tc-99m window was determined for each experi-
ment and subtracted from Tc-99m sestamibi activity after 
correction for radioactivity decay. 
l\leasurement of myocardial blood flow. Myocardial blood 
flow was determined with the microsphere technique (25): 
MBF = Ct x Fw/Ab. 
where MBF is the myocardial blood flow (ml/min per g), Ct 
is the activity in the myocardial tissue sample (cpm/g), Fw is 
the reference blood flow pump withdrawal rate and Ab is the 
activity in the entire reference blood sample (cpm). 
Measurement of absolute tracer retention. Absolute 
tracer retention was calculated as follows: 
R(t) = Ct(t)'l'Cb(T) d(T), 
where R is the retention (ml/min per g) of the tracer (t), Ct is 
the radioactivity of the tracer in the myocardium (cpm/g), Cb 
is the arterial radioactivity concentration (cpm/ml) and it Cb( r) d( r) is the time-integral of Cb. 
Measurement of percent maximal tracer retention. For 
further comparison of myocardial tracer retention the per-
cent maximal retention for each tracer was also calculated as 
follows: 
JACC Vol. 20, No.5 MELON ET AL. 1279 
November I, 1992:1277-83 MYOCARDIAL RETENTION OF PERFUSION TRACERS 
Table 1. Summary of Experimental Data 
Tc-99m Sestamibi Fit Thallium-201 Fit 
Time After Dog No. of Flow Range 
R = a MBF (I_e-b/MBF) 
Correlation 
R = a MBF (I_e-b:~IBF) 
Correlation 
Injection No. Samples (mVmin per g) a b (r) a b (r) 
2 min 58 0.32-5.91 0.14 4.45 0.9.t 0.51 8.31 0.99 
2 min 2 56 0.O.t-7.13 0.12 10.70 0.98 0.33 19.14 0.99 
Average 0.13 ± 0.02 7.58 ± 4.42 0.42 ± 0.12 13.73 ± 7.66 
5 min 3 82 0.02-5.4.t O.ll 6.79 0.98 0.52 11.l7 0.98 
5 min 4 86 0.01-5.51 0.16 6.99 0.98 0.47 9.74 0.99 
5 min 5 5.t 0.23-3.95 0.14 6.62 0.92 0.50 6.37 0.96 
Average 0.13 ± 0.02 6.80 ± 0.19 0.49 ± 0.03 9.09 ± 2.47 
20 min 6 64 0.02-7.11 0.15 5.55 0.98 0.32 7.02 0.99 
20 min 7 60 0.02-2.95 0.22 2.52 0.98 0.42 4.35 0.99 
20 min 8 92 0.05-2.60 0.23 2.79 0.9.t 0.49 3.00 0.97 
20 min 9 56 0.02-5.50 0.11 5.00 0.79 0.27 5.00 0.97 
Average 0.16 ± 0.06 3.97 ± 1.53 0.38 + 0.10 4.84 + 1.67 
a and b constants; MBF - myocardial blood flow; R - retention; Tc = technetium. 
%Rmax = 100 x RfRmax, 
where Rmax is the maximal tissue retention in an individual 
heart for the tracer and R is the tissue retention of the tracer 
for the considered myocardial segment. 
Measurement of normalized retention. For further com-
parison of tissue retention between the tracers, the normal-
ized tissue retention was also calculated. For each dog the 
absolute myocardial retention of Tc-99m sestamibi and thal-
lium-201 for each segment was plotted against the micro-
sphere-determined blood flow. Each retention versus blood 
flow curve was fitted to the nonlinear function: 
R = a MBF (1 - e-bIMBF), [I] 
where R = retention, a and b = real constants, MBF = 
myocardial blood flow. Myocardial tissue retention values 
were calculated at a flow range of I, 2, 3, 4 and 5 ml/min per 
g based on the average of constants of the fitted equations for 
each group of dogs. The calculated retention was then 
expressed as a percent of retention determined at a flow rate 
of I mllmin per g. The increment of tissue retention was also 
calculated between each level of blood flow rate. 
Statistical analysis. All values are expressed as mean 
value ± I SO. Blood pressure and heart rate at baseline 
after dipyridamole, before and after tracers and micro: 
spheres injection were compared by paired t test. Multivari-
ate linear regression analysis was used to test the presence of 
a slope different from 0 for the relation between the retention 
and the microsphere-determined blood flow within three 
selected intervals of flow from I to 3, 3 to 5 and >5 mllmin 
per g. Individual dogs were treated as blocking variables. A 
p value >0.05 was considered not significant. 
Results 
Hemodynamic recordings. At baseline, before dipyrida-
mole injection, the mean systolic pressure was 140 ± 
22 mm Hg and the heart rate 160 ± 17 beats/min. After 
dipyridamole infusion, the systolic blood pressure decreased 
to 123 ± 29 mm Hg (p < 0.05) and the heart rate was 158 ± 
25 beats/min (p = NS). At the time of tracer and microsphere 
injection, systolic blood pressure and heart rate were 123 ± 
28 mm Hg and 159 ± 33 beats/min, respectively, and 
remained stable thereafter. 
l'tlicrosphere-determined blood flow. Myocardial blood 
flow was determined in a total number of 114, 222 and 
272 tissue samples in groups I, II and III, respectively. 
Microsphere-determined blood flow ranged from 0.04 to 
7.13 ml/min per g in group I, from 0.01 to 5.51 ml/min per g 
in group II and from 0.02 to 7.1 I mllmin per g in group III. 
Absolute myocardial retention. Absolute myocardial re-
tention was calculated for each tissue sample. Table I shows 
the nonlinear fitted parameter estimates and correlation 
coefficients for all the experiments in the three groups. 
Figure 2A shows an individual example of retention flow 
relation for both tracers from each group. The absolute 
retention of thallium-20l was much greater than that of 
Tc-99m sestamibi. At 2 min after injection, absolute tissue 
retention for thallium-201 was 3.36 and 3.94 times greater 
than that for Tc-99m sestamibi at flow values of 2 and 
5 mllmin per g, respectively. At 20 min after injection, it was 
2.14 and 2.68 times greater than that for Tc-99m sestamibi at 
the same two levels of flow, respectively. The decrease in 
the thallium-201ITc-99m sestamibi retention ratio over time 
indicated greater back diffusion of thallium-201. 
Percent maximal myocardial retention. Percent maximal 
myocardial retention was also calculated for each dog in the 
three groups. Figure 2B shows data of Figure 2A expressed 
in percent maximal myocardial retention. At 2 min after 
injection, the increase of relative retention for both tracers 
was linear in relation to blood flow over a wide flow range. 
The linear relation is lost at higher flow rates over time; 
Tc-99m sestamibi retention data were more scattered than 
were thallium-201 data at higher flow rates. 
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Figure 2. A, Examples of thallium-20l and 
technetium-99m (Tc-99m) sestamibi abso-
lute retention versus microsphere-deter-
mined myocardial blood flow (MBF) at 2, 
5 and 20 min after injection. B, Percent of 
maximal retention versus myocardial 
blood flow (MBF) for thallium-20l and 
Tc-99m sestamibi. At 2 min after injection, 
the linear relation was well maintained 
over the wide range of flow. The Tc-99m 
sestamibi data were more scattered at 
higher flow rates. Both tracers underesti-
mate blood flow at higher flow rates. 
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Normalized retention. The normalized retention ex-
pressed as a percent of retention at a blood flow of I mllmin 
per g is presented in Table 2, which also shows the retention 
increments for both tracers between each level of blood 
flow. For each time point, increments of relative retention 
were always larger for thallium-201 than for Tc-99m ses-
tamibi between the different blood flow levels over the entire 
range of blood flow. For both tracers, retention increments 
decreased as flow increased. Considering different amplitude 
of retention increment between each level of flow for Tc-99m 
sestamibi and thallium-201, a multivariate linear regression 
Table 2. Normalized Retention Correlated With Myocardial 
Blood Flow 
Myocardial Blood Flow (mlfmin per g) 
2 3 4 5 
2 min 
Tc-99m sestamibi 100 196 (96) 276 (80) 340 (64) 390 (50) 
Thallium-201 100 200 (100) 297 (97) 387 (100) 468 (81) 
5 min 
Tc-99m sestamibi 100 194 (94) 269 (75) 327 (58) 372 (45) 
Thallium-201 100 198 (98) 286 (88) 359 (73) 419 (60) 
20 min 
Tc-99m sestamibi 100 176 (76) 224 (48) 257 (33) 279 (22) 
Thallium-201 100 184 (84) 242 (58) 283 (41) 313 (30) 
All values are expressed as a percent. The increment of retention between 
each level of myocardial blood flow is presented in parentheses. Tc = 
technetium. 
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analysis was used to assess whether it may represent a 
different ability to evaluate blood flow changes for both 
tracers. The statistical analysis tested the presence of a slope 
different from 0 for the relation between the retention and 
the microsphere-determined blood flow within three selected 
intervals of flow. The slope was not different from 0 for 
Tc-99m sestamibi in comparison with thallium-201 for the 
intervals of flow of3 to 5 and >5 ml/min per g at 20 min after 
injection and for the interval of flow >5 ml/min per g at 5 min 
after injection (Table 3). 
Discussion 
Absolute tissue retention of a tracer represents its ability 
to accumulate in the tissue as a function of delivery to the 
tissue. However, clinically more relevant is the relation of 
retention of the tracer to blood flow. This relation defines the 
accuracy of the tracer to determine tissue flow over a wide 
blood flow range. Extraction and retention of a tracer by 
tissue are determined by its diffusion or carrier-mediated 
transport across endothelial and sarcolemmal barriers, or 
both, and subsequent steps of transport or metabolism, or 
both. The delivery of the tracer is proportional to myocardial 
blood flow. As flow increases, the maximal initial extraction 
(peak extraction) for most tracers tends to decrease. This 
decrease of tracer extraction results in an underestimation of 
the "true" increase in blood flow as assessed by tissue tracer 
uptake. A high extraction or retention fraction indicates the 
lACC Vol. 20, No.5 
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Table 3. Statistical Significance of Linear Regression Coefficients 
of Retention Versus Myocardial Blood Flow 
Range of Flow (ml/min per g) 
I to 3 3 to 5 >5 
2 min 
Tc-99m sestamibi <0.0001 <0.0001 <0.0001 
(2,10) (2.37) (2,56) 
Thallium-201 <0.0001 <0.0001 <0.0001 
5 min 
Tc-99m sestamibi <0.0001 <0.001 NS 
(3,58) (3,111) (2,9) 
Thallium-201 <0.0001 <0.0001 <0.05 
20 min 
Tc-99m sestamibi <0.001 NS NS 
(4,135) (2,48) (2,34) 
Thallium-201 <0.0001 <0.005 <0.001 
Data are presented as p values. Values in parentheses indicate the number 
of dogs and myocardial samples counted in each interval of myocardial blood 
flow. Analysis was performed by multivariate linear regression. Tc = tech-
netium. 
suitability of a flow tracer to adequately assess higher flow 
rates, such as those encountered during pharmacologic 
coronary vasodilation. It is equally important that the tissue 
activity remain stable during the time of cardiac imaging 
which, in the case of Tc-99m sestamibi, usually begins 
30 min after tracer injection. The biologic half-life of tracer in 
tissue depends on the clearance rate of the tracer from the 
tissue. Back diffusion may lead to underestimation of myo-
cardial perfusion during delayed cardiac imaging. Thus, both 
initial extraction and subsequent retention by the myocar-
dium define suitabIlity of a given tracer for flow studies. 
Absolute and relative tracer retention. The present study 
demonstrates that absolute tissue retention of thallium-201 
was greater than that of Tc-99m sestamibi. Tissue retention 
of both tracers underestimated blood flow at higher flow 
levels but thallium-201, as compared with Tc-99m sestamibi, 
was characterized by larger increments of relative tracer 
retention between different levels of blood flow. Our results 
are supported by previous studies. Recently, Edwards et al. 
(26) reported that thallium-201 and Tc-99m sestamibi relative 
uptake did not increase proportionally to blood flow during 
adenosine infusion; the increase in Tc-99m sestamibi was 
always less than that of thallium-20l. . 
Using isolated rabbit heart preparations and a multi-
indicator technique, Leppo and Meerdink (20) calculated 
peak extraction, net extraction (= retention) and capillary 
permeability surface area product for thallium-201 and Tc-99m 
sestamibi in a range of flow from 0.56 to 3.19 mlfmin per g. 
They showed that peak extraction and net extraction were 
greater for thallium-201 than for Tc-99m sestamibi. For both 
tracers the peak extraction and net extraction demonstrated 
a negatively sloped linear relation to blood flow. In our study 
the myocardial retention versus myocardial blood flow 
curves for both thallium-201 and Tc-99m sestamibi were 
empirically described by the function in equation I. The 
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Crone model (27) used by Leppo and Meerdink (20), which 
assumes no back diffusion of tracer, is of similar form: 
R = flow x extraction = MBF (I - e -PScapIMBF), 
where PScap is the product of capillary permeability and 
surface area. Although a strict relation between the param-
eter band PS cannot be expected because our measurements 
do not account for the influence of tracer back flux, the 
decrease in b with time of measurement (Table l) is consis-
tent with increasing underestimation of tracer extraction 
(through PS) as the fraction of tracer undergoing back 
diffusion increases. 
Pe"rcent maximal tracer retention. At 2 min after tracer 
injection, our study demonstrates a nearly linear relation 
between percent maximal retention of both thallium-20l and 
Tc-99m sestamibi and myocardial blood flow over a wide 
range of blood flow induced by intravenous infusion of 
dipyridamole. However, thallium-201 tissue retention was 
more closely related to blood flow than was Tc-99m sesta-
mibi at higher flow rates; this early superiority of thallium-
20 1 was lost at 20 "min after injection because of its greater 
back diffusion. Twenty minutes after injection, both tracers 
had greater underestimation of regional blood flow differ-
ences at higher flow rates. However, despite its greater back 
diffusion as compared with Tc-99m sestamibi, thallium-201 
evaluated blood flow changes more efficiently. 
Previously, using the isolated rabbit heart model, Mar-
shall et al. (21) evaluated thallium-201 and Tc-99m sestamibi 
uptake (flow x net extraction) immediately and to and 
30 min after injection for a range of flow of 0.5 to 3.5 mllmin 
per g. Immediately after thallium-2Ot injection, uptake of the 
tracer was closer to the line of identity for a range of flow 
between 0.5 and 2 mllmin per g. At flow rates above 2 mllmin 
per g, the uptake of both tracers tended to underestimate 
blood flow. The transport limitation on tracer uptake ap-
peared to be more pronounced for Tc-99m sestamibi than for 
thallium-20l. At to and 30 min after injection, relative 
uptake of both tracers underestimated changes in flow rates 
over the range of perfusion rates. Our results are in agree-
ment with these findings, although we used an in vivo model 
with dipyridamole infusion, inducing a larger range of blood 
flow. 
Validity of the animal model. Dipyridamole infusion and 
left anterior descending coronary artery occlusion allow a 
wide range of blood flow rates to be obtained. By counting 
numerous myocardial segments, the relation between tracer 
retention and flow can be determined at the different flow 
levels over the wide flow range. In each time group, there is 
some variability in the fitted equations describing the data. 
This could be due in part to the different range of blood flow 
between the dogs: A small variation in the length and the 
position of the catheter in the left atrium c{)uld also modify 
the delivery time of the tracers to the myocardium early after 
injection. 
In this study the dosages of Tc-99m sestamibi and thal-
lium-201 were chosen for counting purposes. The injected 
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doses were dependent on the maximal count rate of the well 
counter. Furthermore, because of simultaneous tracer injec-
tion, the higher doses of Tc-99m sestamibi minimized the 
relative spillover of thallium-201 activity into the Tc-99m 
sestamibi window at the time of counting. As thallium-201 
activity was counted after decay of Tc-99m sestamibi, there 
was no spillover of Tc-99m activity into the thallium win-
dow. Because in vitro counting was used, it is unlikely that 
the chosen dosage for each tracer may have influenced the 
results of this study. 
Clinical imaging implications. The clinical implication of 
the study is that thallium-201 tissue retention more closely 
represents myocardial blood flow changes than does that of 
Tc-99m sestamibi. Of course, this does not consider image 
quality related to physical properties of thallium-20 I, be-
cause the data were acquired in a well counter and not by an 
imaging technique. Furthermore, external detection of myo-
cardial activity with use of a gamma camera may also be 
inferior in resolving differences of tracer retention corre-
sponding to blood flow changes. Our results also imply that 
for both tracers early image acquisition minimizes the un-
derestimation of blood flow differences at higher flow. 
Several clinical studies (11,13-16,28,29) reported similar 
sensitivity and specificity for thallium-201 and Tc-99m ses-
tamibi in the detection of coronary artery disease. These 
studies were based on evaluation of relative difference of 
regional tracer activity in the myocardium. For both tracers 
tomographic imaging, as compared with planar imaging, 
improved the detection of the diseased arteries. However, at 
present there is no clear evidence that Tc-99m sestamibi 
offers significant advantages over thallium-201 for the detec-
tion of coronary disease. The better image quality of Tc-99m 
sestamibi may be offset by less suitable physiologic charac-
teristics of this flow tracer. Furthermore, no large clinical 
studies employing pharmacologic vasodilation have been 
performed comparing the diagnostic accuracy of Tc-99m 
sestamibi and thallium-201 for the detection of coronary 
artery disease, although recently Eisner et al. (30) compared 
the myocardial distribution of these tracers in dogs with 
partial and total coronary artery occlusion during adenosine 
infusion. Using a polar map display, they showed that 
Tc-99m sestamibi in comparison with thallium-201 underes-
timated the size of underperfused territories related to the 
partially occluded vessel. Inversely, the size of the defect 
determined by both tracers was similar after total coronary 
artery occlusion. Thus, these results also suggest that Tc-
99m sestamibi may be less accurate than thallium-201 in the 
detection of reduced coronary flow reserve in myocardial 
territories suspended by mild coronary artery stenosis dur-
ing pharmacologic vasodilation. 
Conclusions. Thallium-201 and Tc-99m sestamibi are 
characterized by different kinetic properties. Thallium-201 
demonstrates greater absolute tissue retention than does 
Tc-99m sestamibi. Early after injection, there is a well 
maintained relation between the tissue retention of both 
tracers and blood flow, although retention of both tracers 
lAce Vol. 20, No.5 
November 1.1992:1277-83 
underestimates blood flow at higher flow rates. Overall, 
thallium-201 retention characteristics may allow better dif-
ferentiation of regions with different coronary flow reserve. 
Additional clinical studies will have to compare Tc-99m 
sestamibi and thallium-201 accuracy for the detection of 
coronary disease during coronary pharmacologic vasodila-
tion and determine whether Tc-99m sestamibi accuracy may 
be inferior to that of thallium-20 I in the detection of patients 
with mild coronary artery disease. 
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